Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort

Lucia Macken, William Gelson, Matthew Priest, George Abouda, Stephen Barclay, Andrew Fraser, Brendan Healey, Will Irving, Sumita Verma

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Direct-acting antivirals (DAAs) have revolutionised the management of chronic hepatitisC virus (HCV) infection. We describe UK real-world DAA experience. Individualscommencing HCV treatment containing a DAA regimen (Mar 2014-Nov 2016),participating in the National HCV Research UK (HCVRUK) Cohort Study were recruitedfrom 33 UK HCV centers. The data were prospectively entered at sites onto acentralised database. The data were reported as median (Q1-Q3). Of the 1448 treatedpatients, 1054 (73%) were males, the median age being 54 years (47-60), 900 (62%)being genotype 1 and 455 (31%) genotype 3. The majority, 887 (61%) had cirrhosis, and590 (41%) were treatment-experienced. DAA regimens utilised: genotype1 sofosbuvir(SOF)/Ledipasvir/±Ribavirin (625/900, 69%) and Ombitasvir/Paritaprevir/Dasabuvir/±RBV (220/900, 24%), and in genotype 3 SOF/Daclatasvir + RBV (256/455, 56%) andSOF/pegylated interferon/RBV (157/455, 35%). Overall, 1321 (91%) achieved sustainedvirological response (SVR12), genotype 1 vs 3, 93% vs 87%, P < .001. Prior treatment,presence of cirrhosis and treatment regimen did not impact SVR12. Predictors oftreatment failure were genotype 3 infection, OR, 2.015 (95% CI: 1.279-3.176, P = .003),and male sex, OR, 1.878 (95% CI: 1.071-3.291, P = .028). Of those with hepaticdecompensation at baseline (n = 39), 51% (n = 20) recompensated post-treatment, lowerbaseline serum creatinine being associated with recompensation (P = .029). There weretwo liver-related deaths, both having decompensated disease. This real-world UK data,comprising of a predominantly cirrhotic HCV genotype 1/3 cohort, confirms DAAefficacy with an overall 91% SVR12, with 51% recompensating post-treatment.Genotype 3 infection was a predictor of treatment failure.
Original languageEnglish
Pages (from-to)1979-1988
Number of pages10
JournalJournal of Medical Virology
Issue number11
Early online date22 Jul 2019
Publication statusPublished - Nov 2019


  • genotype 1
  • genotype 3
  • hepatic decompensation
  • hepatic recompensation
  • SVR12
  • treatment failure
  • Hepatitis C


Dive into the research topics of 'Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort'. Together they form a unique fingerprint.

Cite this